Skip to content
Companies

Biomark Diagnostics

Blood tests for early lung, breast and pancreatic cancer

Raised to date

$2.5M

of $2.5M offered across 1 Form D filing

Investors
10
Last filed
Apr 14, 2025

About

BioMark Diagnostics Inc. is dedicated to tackling the critical global issue of early cancer detection, particularly focusing on cancers that are notoriously difficult to diagnose, such as lung, breast, and pancreatic cancers. Their diagnostic solutions aim to significantly improve patient outcomes through earlier and more accurate detection, which is essential for effective treatment and increased survival rates.

Non-invasive liquid biopsy approach

Funding

  • EquityFiled Apr 14, 2025Form D
    $2.5M/ $2.5M

Product

Liquid Biopsy Diagnostic Technologies

In-vitro diagnostics

BioMark specializes in cutting-edge liquid biopsy diagnostic technologies that harness the power of metabolomics and machine learning to detect cancer-associated biomarkers from simple blood samples. By analyzing these biomarkers, the platform enables early-stage cancer detection, monitors patient responses to treatments, and facilitates routine monitoring for cancer survivors.

  • Early-stage cancer detection
  • Monitoring patient responses to treatments
  • Routine cancer survivor monitoring

Built for

Healthcare Providers and Clinical Researchers

People on file